Cubist, Teva Settle IP Suit Over Generic Cubicin
Cubist Pharmaceuticals Inc. struck a licensing deal with Teva Pharmaceutical Industries Ltd. on Monday to resolve patent infringement litigation over a proposed generic version of Cubist's IV antibiotic Cubicin, allowing Teva...To view the full article, register now.
Already a subscriber? Click here to view full article